Biomarker Shows Promise In Scleroderma PDF Print E-mail
Thursday, 23 May 2013 21:16
A biomarker that can be used to screen Scleroderma patients for pulmonary hypertension has shown promise in a proof of concept study. Researchers from St Vincent’s in Melbourne found asymmetric dimethylarginine (ADMA) levels had an acceptable high specificity and sensitivity for detecting the complication, particularly when used in conjunction with NT-proBNP.

When combined with the biomarker commonly used in heart failure the test had a sensitivity of 93.3% and a specificity of 100% for detecting PAH, said author Vivek Thakker (pictured) from St Vincent’ in Melbourne who presented his poster during a tour led by Wendy Stevens from the same hospital.

Testing for ADMA was not widely available but cost $60 a test, significantly cheaper than echocardiography, he said.

But the results needed to be validated in larger cohorts, he added.

Source: Rheumatology Update (2013)
 
More articles :

» Managing Your Digical Ulcer

Around 40% of patients with develop open sores on their fingertips called digital ulcers. In some patients, this is the major ongoing difficulty whereas in others, digital ulcers are an uncommon and short term complication.Digital ulcers occur...

» A System Out of Breath: How Hypoxia Possibly Contributes to the Pathogenesis of Systemic Sclerosis

T. W. van Hal, L. van Bon, and T. R. D. J. RadstakeReceived 20 May 2011; Revised 18 August 2011; Accepted 7 September 2011Systemic sclerosis (SSc) is typified by vascular alterations and immunological disturbances and fibrosis of the skin and...

» Unite Against Scleroderma

On May 1st 2011, the would be holding its first annual "Unite Against Scleroderma" Walk around the Queen's Park Savannah, Port Of Spain. It is our aim to help raise awareness of this rare autoimmune disease and the funding needed to aid those who...

» Researchers Identify Core Genetic Switch As A Viable Target For New Scleroderma Treatments

Scleroderma is a rare, autoimmune disease. Often fatal, it causes the fibrosis or thickening of the connective tissue which support the skin and other vital organs within the body, through the overproduction of . The disease currently lacks a cure...

» Juvenile Localized Scleroderma: Fewer Flares With Methotrexate

was an effective and well-tolerated treatment for in a randomized, double-blind, placebo-controlled trial involving 70 patients with active disease. At the end of the 12-month study, 31 of 46 patients randomized to receive methotrexate had...

» Development of an Activity Index for Localized Scleroderma (Morphea)

E. Lanciano, A. CHIALà, E. Praino, V. Grattagliano, M. Covelli, F. Iannone, G. Lapadula Reumatologia Universitaria, Policlinico, Bari, ItalyAnn Rheum Dis 2011;70(Suppl3):481Background: Morphea is a skin disorder characterized by fibrosis. It...